Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.97
ESALY's Cash to Debt is ranked lower than
62% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. ESALY: 0.97 )
Ranked among companies with meaningful Cash to Debt only.
ESALY' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 0.97 Max: 3902.8
Current: 0.97
0.3
3902.8
Equity to Asset 0.59
ESALY's Equity to Asset is ranked lower than
56% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ESALY: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
ESALY' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.59 Max: 0.7
Current: 0.59
0.37
0.7
Interest Coverage 14.75
ESALY's Interest Coverage is ranked lower than
56% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. ESALY: 14.75 )
Ranked among companies with meaningful Interest Coverage only.
ESALY' s Interest Coverage Range Over the Past 10 Years
Min: 5.79  Med: 13.36 Max: 1619.43
Current: 14.75
5.79
1619.43
F-Score: 5
Z-Score: 4.35
M-Score: -2.65
WACC vs ROIC
5.60%
9.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 9.48
ESALY's Operating margin (%) is ranked higher than
53% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. ESALY: 9.48 )
Ranked among companies with meaningful Operating margin (%) only.
ESALY' s Operating margin (%) Range Over the Past 10 Years
Min: 2.42  Med: 11.79 Max: 15.61
Current: 9.48
2.42
15.61
Net-margin (%) 10.04
ESALY's Net-margin (%) is ranked higher than
65% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. ESALY: 10.04 )
Ranked among companies with meaningful Net-margin (%) only.
ESALY' s Net-margin (%) Range Over the Past 10 Years
Min: -2.32  Med: 8.17 Max: 10.47
Current: 10.04
-2.32
10.47
ROE (%) 9.30
ESALY's ROE (%) is ranked higher than
58% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. ESALY: 9.30 )
Ranked among companies with meaningful ROE (%) only.
ESALY' s ROE (%) Range Over the Past 10 Years
Min: -3.4  Med: 10.20 Max: 16.4
Current: 9.3
-3.4
16.4
ROA (%) 5.46
ESALY's ROA (%) is ranked higher than
61% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. ESALY: 5.46 )
Ranked among companies with meaningful ROA (%) only.
ESALY' s ROA (%) Range Over the Past 10 Years
Min: -1.78  Med: 4.57 Max: 9.17
Current: 5.46
-1.78
9.17
ROC (Joel Greenblatt) (%) 23.99
ESALY's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. ESALY: 23.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESALY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.99  Med: 27.90 Max: 56.21
Current: 23.99
7.99
56.21
Revenue Growth (3Y)(%) -1.60
ESALY's Revenue Growth (3Y)(%) is ranked lower than
71% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. ESALY: -1.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESALY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.75 Max: 12
Current: -1.6
0
12
EBITDA Growth (3Y)(%) -12.10
ESALY's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. ESALY: -12.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESALY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 1.85 Max: 45
Current: -12.1
0
45
EPS Growth (3Y)(%) 4.20
ESALY's EPS Growth (3Y)(%) is ranked lower than
56% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. ESALY: 4.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESALY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.3  Med: 6.60 Max: 53.8
Current: 4.2
-21.3
53.8
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:SGIOY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:APNHY, OTCPK:MTZPY, NAS:MYL, NYSE:ZTS, OTCPK:HLUYY, NYSE:VRX, NYSE:RDY, NYSE:MNK, OTCPK:MDABY, NYSE:TARO, NAS:OPK, OTCPK:HYPMY, OTCPK:IPSEY, NAS:NBIX, NAS:AKRX, NAS:ENDP, NYSE:CTLT » details
Traded in other countries:EII.Germany, 4523.Japan,
Eisai Co Ltd is a healthcare company. It is engaged in providing prescription pharmaceuticals, consumer health care products, and diagnostics services.

Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.

Ratios

vs
industry
vs
history
P/E(ttm) 32.07
ESALY's P/E(ttm) is ranked lower than
57% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. ESALY: 32.07 )
Ranked among companies with meaningful P/E(ttm) only.
ESALY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 24.72 Max: 119.42
Current: 32.07
12.4
119.42
PE(NRI) 32.07
ESALY's PE(NRI) is ranked lower than
56% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.39 vs. ESALY: 32.07 )
Ranked among companies with meaningful PE(NRI) only.
ESALY' s PE(NRI) Range Over the Past 10 Years
Min: 12.4  Med: 24.73 Max: 119.43
Current: 32.07
12.4
119.43
Price/Owner Earnings (ttm) 17.01
ESALY's Price/Owner Earnings (ttm) is ranked higher than
77% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. ESALY: 17.01 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ESALY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.36  Med: 17.93 Max: 32.36
Current: 17.01
10.36
32.36
P/B 3.05
ESALY's P/B is ranked lower than
53% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. ESALY: 3.05 )
Ranked among companies with meaningful P/B only.
ESALY' s P/B Range Over the Past 10 Years
Min: 1.76  Med: 2.30 Max: 4.2
Current: 3.05
1.76
4.2
P/S 3.19
ESALY's P/S is ranked lower than
56% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. ESALY: 3.19 )
Ranked among companies with meaningful P/S only.
ESALY' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.99 Max: 6.6
Current: 3.19
0.96
6.6
PFCF 31.61
ESALY's PFCF is ranked lower than
62% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. ESALY: 31.61 )
Ranked among companies with meaningful PFCF only.
ESALY' s PFCF Range Over the Past 10 Years
Min: 5.75  Med: 19.30 Max: 206.63
Current: 31.61
5.75
206.63
POCF 18.35
ESALY's POCF is ranked lower than
57% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. ESALY: 18.35 )
Ranked among companies with meaningful POCF only.
ESALY' s POCF Range Over the Past 10 Years
Min: 4.92  Med: 13.01 Max: 69.65
Current: 18.35
4.92
69.65
EV-to-EBIT 32.61
ESALY's EV-to-EBIT is ranked lower than
70% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. ESALY: 32.61 )
Ranked among companies with meaningful EV-to-EBIT only.
ESALY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 15.30 Max: 85.2
Current: 32.61
6.2
85.2
EV-to-EBITDA 19.98
ESALY's EV-to-EBITDA is ranked lower than
59% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. ESALY: 19.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESALY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 9.40 Max: 36.6
Current: 19.98
4.5
36.6
Shiller P/E 31.39
ESALY's Shiller P/E is ranked higher than
70% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.39 vs. ESALY: 31.39 )
Ranked among companies with meaningful Shiller P/E only.
ESALY' s Shiller P/E Range Over the Past 10 Years
Min: 27.62  Med: 33.91 Max: 37.3
Current: 31.39
27.62
37.3
Current Ratio 2.89
ESALY's Current Ratio is ranked higher than
60% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ESALY: 2.89 )
Ranked among companies with meaningful Current Ratio only.
ESALY' s Current Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.30 Max: 3.23
Current: 2.89
0.77
3.23
Quick Ratio 2.42
ESALY's Quick Ratio is ranked higher than
61% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. ESALY: 2.42 )
Ranked among companies with meaningful Quick Ratio only.
ESALY' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 2.03 Max: 2.87
Current: 2.42
0.66
2.87
Days Inventory 153.99
ESALY's Days Inventory is ranked lower than
69% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. ESALY: 153.99 )
Ranked among companies with meaningful Days Inventory only.
ESALY' s Days Inventory Range Over the Past 10 Years
Min: 146.81  Med: 158.37 Max: 170.66
Current: 153.99
146.81
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.21
ESALY's Dividend Yield is ranked higher than
71% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ESALY: 2.21 )
Ranked among companies with meaningful Dividend Yield only.
ESALY' s Dividend Yield Range Over the Past 10 Years
Min: 1.7  Med: 3.82 Max: 6.71
Current: 2.21
1.7
6.71
Dividend Payout 0.78
ESALY's Dividend Payout is ranked lower than
82% of the 379 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. ESALY: 0.78 )
Ranked among companies with meaningful Dividend Payout only.
ESALY' s Dividend Payout Range Over the Past 10 Years
Min: 0.21  Med: 0.60 Max: 1.3
Current: 0.78
0.21
1.3
Forward Dividend Yield 2.50
ESALY's Forward Dividend Yield is ranked higher than
67% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. ESALY: 2.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.22
ESALY's Yield on cost (5-Year) is ranked higher than
57% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. ESALY: 2.22 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ESALY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.7  Med: 3.82 Max: 6.71
Current: 2.22
1.7
6.71
3-Year Average Share Buyback Ratio -0.10
ESALY's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. ESALY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESALY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: 0.05 Max: 1.3
Current: -0.1
-1.3
1.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 37.03
ESALY's Price/Net Current Asset Value is ranked lower than
91% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. ESALY: 37.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ESALY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.45  Med: 7.83 Max: 124.02
Current: 37.03
4.45
124.02
Price/Tangible Book 5.96
ESALY's Price/Tangible Book is ranked lower than
69% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.59 vs. ESALY: 5.96 )
Ranked among companies with meaningful Price/Tangible Book only.
ESALY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.74  Med: 4.40 Max: 31.78
Current: 5.96
1.74
31.78
Price/Projected FCF 1.60
ESALY's Price/Projected FCF is ranked higher than
69% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. ESALY: 1.60 )
Ranked among companies with meaningful Price/Projected FCF only.
ESALY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.26 Max: 2.12
Current: 1.6
1.05
2.12
Price/Median PS Value 1.61
ESALY's Price/Median PS Value is ranked lower than
73% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. ESALY: 1.61 )
Ranked among companies with meaningful Price/Median PS Value only.
ESALY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 0.99 Max: 2.24
Current: 1.61
0.54
2.24
Price/Graham Number 2.91
ESALY's Price/Graham Number is ranked lower than
65% of the 500 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.19 vs. ESALY: 2.91 )
Ranked among companies with meaningful Price/Graham Number only.
ESALY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.11  Med: 2.09 Max: 4.61
Current: 2.91
1.11
4.61
Earnings Yield (Greenblatt) (%) 3.08
ESALY's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ESALY: 3.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESALY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 6.50 Max: 16
Current: 3.08
1.2
16
Forward Rate of Return (Yacktman) (%) -11.97
ESALY's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. ESALY: -11.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESALY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.6  Med: 3.40 Max: 22.4
Current: -11.97
-13.6
22.4

More Statistics

Revenue (TTM) (Mil) $4,576
EPS (TTM) $ 1.61
Beta-0.19
Short Percentage of Float0.00%
52-Week Range $53.55 - 70.24
Shares Outstanding (Mil)285.94
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in... Jul 22 2016
Eisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets Jul 19 2016
Arena Pharma stock rises 8.8% after weight-loss drug is approved Jul 19 2016
Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico Jul 14 2016
Japan's Eisai weighs legal action in UK cancer drug row Jul 07 2016
Eisai Calls for Immediate Solution to Rare Cancers Black Hole Jul 07 2016
ETF’s with exposure to Eisai Co., Ltd. : July 5, 2016 Jul 05 2016
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible... Jun 30 2016
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1% Jun 24 2016
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human... Jun 20 2016
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the... Jun 16 2016
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in... Jun 02 2016
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal... Jun 01 2016
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) May 25 2016
Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting May 23 2016
ETF’s with exposure to Eisai Co., Ltd. : May 19, 2016 May 19 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q4, 2016 By the Numbers May 17 2016
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with... May 15 2016
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY May 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)